Printer Friendly

Notice Of Allowance For Metabolic Patent In The U.S.

MELVILLE, N.Y., November 15, 2018 -- Bio-Restorative Therapies, Inc. (BRTX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance on its patent application related to a human brown adipose tissue differentiated cell, which is part of the company's metabolic (ThermoStem) program.

When issued in the U.S., the final patent will protect a human brown adipose tissue differentiated cell derived from an isolated human brown adipose tissue stem cell.

The differentiated cell is designed for potential therapeutic uses for treating a wide range of degenerative and metabolic disorders, including but not limited to diabetes, obesity, hypertension, and cardiac deficiency.

This will be the fourth patent issued for the company's brown fat metabolic program, and follows a patent issued in the U.S. in September 2015, Australia in April 2017, and Japan in December 2017.

CEO Mark Weinreb said the notice offers protection for the specific cell line identified for the metabolic product to be used in future preclinical/clinical testing.


COPYRIGHT 2018 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Patent News
Publication:Stem Cell Business News
Date:Nov 26, 2018
Previous Article:Company Submits FDA IND For Stem Cell Therapy In Progressive MS.
Next Article:Researchers Find Brain, Muscle Cells In Lab-Grown Kidney Organoids: Is There A Simple Way To Retard Development Of Wayward Cells?

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |